Aclaris Therapeutics, Inc.ACRSNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank67
3Y CAGR-12.2%
5Y CAGR+12.4%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-12.2%/yr
vs +5.4%/yr prior
5Y CAGR
+12.4%/yr
Recent deceleration
Acceleration
-17.6pp
Decelerating
Percentile
P67
Within normal range
vs 5Y Ago
1.8x
Solid growth
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
2025$52.65M+56.7%
2024$33.59M-65.9%
2023$98.38M+26.4%
2022$77.81M+77.6%
2021$43.81M+49.3%
2020$29.34M-54.8%
2019$64.90M+3.0%
2018$63.01M+58.4%
2017$39.79M+18.9%
2016$33.48M-